Trial Profile
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MAGE A-10 TCR-transduced lymphocytes (Primary) ; Cyclophosphamide; Fludarabine
- Indications Non-small cell lung cancer
- Focus Adverse reactions; First in man
- Sponsors Adaptimmune
- 08 Apr 2021 Status changed from active, no longer recruiting to completed.
- 05 May 2020 Planned End Date changed from 1 Apr 2034 to 1 Dec 2034.
- 20 Nov 2019 Planned primary completion date changed from 1 Apr 2019 to 1 May 2020.